Boston Scientific: The $5.4 Billion Quarter Tells Me The Sell-Off Is Overdone

Ryan Canady 603 Followers Follow Summary Boston Scientific has been heavily sold off, now trading at attractive valuations versus peers after multiple guidance cuts. Despite U.S. growth headwinds for WATCHMAN and electrophysiology, BSX delivered strong Q2 2026 results with 7.5% sales growth and 14.7% adjusted EPS growth. International markets are driving robust growth for BSX, with electrophysiology up 23.1% and WATCHMAN up 17.7% outside the U.S. Strong free cash flow ($1.29B Q2, $3.8B FY forecast) enables innovation, acquisitions, and potential share repurchases; I rate BSX a strong buy at current levels. MoMo Productions/DigitalVision via Getty Images Boston Scientific ( BSX ) appears to be a name that has been paying heavily for the extremely high expectations placed on it during 2024 and 2025. Over the last year, the stock has lost more than This article was written by Ryan Canady 603 Followers Follow Investing wisely does not have to be rocket science. It is about discipline and running the numbers. You don't have to be like a grandmaster chess player playing the game twenty moves ahead of your opponent, you just need to understand how the pieces work. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.